Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CRO
CRO
FDA qualifies 1st AI drug development tool in MASH
AIM-NASH is meant to help score the different stages of liver biopsy, including fat infiltration, inflammation and scarring.
Gabrielle Masson
Dec 9, 2025 12:12pm
Paradigm snags $78M to revamp CRO space, inks deal with Flatiron
Dec 4, 2025 2:35pm
FDA proposes higher fees for ph. 1 trials conducted outside of US
Dec 3, 2025 5:19pm
Next-gen CRO unveils with access to 350-plus US sites
Dec 3, 2025 3:55pm
FDA issues plan to reduce primate testing for certain antibodies
Dec 2, 2025 11:25am
JSR hands over Crown to Carlyle-backed company in $204M deal
Nov 18, 2025 2:32pm
